Information Collection: “10 CFR Part 35, Medical Use of Byproduct Material”, 24750-24751 [2017-10967]

Download as PDF 24750 Federal Register / Vol. 82, No. 102 / Tuesday, May 30, 2017 / Notices For the Nuclear Regulatory Commission. James G. Danna, Chief, Plant Licensing Branch I–1, Division of Operating Reactor Licensing, Office of Nuclear Reactor Regulation. [FR Doc. 2017–11040 Filed 5–26–17; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [NRC–2017–0013] Information Collection: ‘‘10 CFR Part 35, Medical Use of Byproduct Material’’ Nuclear Regulatory Commission. ACTION: Notice of submission to the Office of Management and Budget; request for comment. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) has recently submitted a request for renewal of an existing collection of information to the Office of Management and Budget (OMB) for review. The information collection is entitled, ‘‘10 CFR part 35, Medical Use of Byproduct Material.’’ DATES: Submit comments by June 29, 2017. SUMMARY: Submit comments directly to the OMB reviewer at: Aaron Szabo, Desk Officer, Office of Information and Regulatory Affairs, OMB clearance number 3150–0010, NEOB–10202, Office of Management and Budget, Washington, DC 20503; telephone: 202– 395–3621, email: oira_submission@ omb.eop.gov. ADDRESSES: FOR FURTHER INFORMATION CONTACT: David Cullison, NRC Clearance Officer, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415–2084; email: INFOCOLLECTS.Resource@nrc.gov. SUPPLEMENTARY INFORMATION: I. Obtaining Information and Submitting Comments sradovich on DSK3GMQ082PROD with NOTICES A. Obtaining Information Please refer to Docket ID NRC–2017– 0013 when contacting the NRC about the availability of information for this action. You may obtain publiclyavailable information related to this action by any of the following methods: • Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC–2017–0013. A copy of the collection of information and related instructions may be obtained without charge by accessing Docket ID NRC–2017–0013 on this Web site. • NRC’s Agencywide Documents Access and Management System VerDate Sep<11>2014 19:59 May 26, 2017 Jkt 241001 (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘ADAMS Public Documents’’ and then select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to pdr.resource@nrc.gov. The supporting statement is available in ADAMS under Accession No. ML16333A028. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. • NRC’s Clearance Officer: A copy of the collection of information and related instructions may be obtained without charge by contacting the NRC’s Clearance Officer, David Cullison, Office of the Chief Information Officer, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415–2084; email: INFOCOLLECTS.Resource@NRC.GOV. B. Submitting Comments The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC posts all comment submissions at https:// www.regulations.gov as well as entering the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information. If you are requesting or aggregating comments from other persons for submission to the OMB, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment submissions into ADAMS. Background Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the NRC recently submitted a request for renewal of an existing collection of information to OMB for review entitled, ‘‘10 CFR part 35, Medical Use of Byproduct Material.’’ The NRC hereby informs potential respondents that an agency may not conduct or sponsor, and that a person is PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 not required to respond to, a collection of information unless it displays a currently valid OMB control number. The NRC published a Federal Register notice with a 60-day comment period on this information collection on February 1, 2017 (82 FR 8959). 1. The title of the information collection: ‘‘10 CFR part 35, Medical Use of Byproduct Material.’’ 2. OMB approval number: 3150–0010. 3. Type of submission: Extension. 4. The form number if applicable: N/A. 5. How often the collection is required or requested: Reports of medical events, doses to an embryo/fetus or nursing child, or leaking source are reportable on occurrence. A specialty board certifying entity desiring to be recognized by the NRC must submit a one-time request for recognition and infrequently revise the information. 6. Who will be required or asked to respond: Physicians and medical institutions holding an NRC license authorizing the administration of byproduct material or radiation from this material to humans for medical use. A specialty board certification entity desiring to have its certifying process and board certificate recognized by the NRC. 7. The estimated number of annual responses: 276,359 ((NRC: 36,313 + 962 recordkeepers = 37,275) + (Agreement States: 232,925 + 6,157 recordkeepers + 2 specialty certification entity = 239,084)). 8. The estimated number of annual respondents: 7,121(NRC: 962 + Agreement states 6,157 + 2 specialty certification entities). 9. An estimate of the total number of hours needed annually to comply with the information collection requirement or request: 1,073,224 hours (NRC Licensees 145,195 hrs. + Agreement States 928,027 hrs. + specialty certifying entities 2 hrs.). 10. Abstract: ‘‘10 CFR part 35, Medical Use of Byproduct Material,’’ contains NRC’s requirements and provisions for the medical use of byproduct material and for issuance of specific licenses authorizing the medical use of this material. These requirements and provisions provide for the radiation safety of workers, the general public, patients, and human research subjects. Part 35 contains mandatory requirements that apply to NRC licensees authorized to administer byproduct material or radiation therefrom to humans for medical use. These requirements also provide voluntary provisions for specialty boards to apply to have their certification processes recognized by the E:\FR\FM\30MYN1.SGM 30MYN1 Federal Register / Vol. 82, No. 102 / Tuesday, May 30, 2017 / Notices NRC so that their board certified individuals can use the certifications as proof of training and experience. Dated at Rockville, Maryland, this 23rd day of May 2017. For the Nuclear Regulatory Commission. David Cullison, NRC Clearance Officer, Office of the Chief Information Officer. [FR Doc. 2017–10967 Filed 5–26–17; 8:45 am] BILLING CODE 7590–01–P SECURITIES AND EXCHANGE COMMISSION [Release No. 34–80747; File No. SR–GEMX– 2017–10] Self-Regulatory Organizations; Nasdaq GEMX, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Regarding the Opening Process May 23, 2017. Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (‘‘Act’’),1 and Rule 19b–4 thereunder,2 notice is hereby given that on May 10, 2017, Nasdaq GEMX, LLC (‘‘GEMX’’ or ‘‘Exchange’’) filed with the Securities and Exchange Commission (‘‘Commission’’) the proposed rule change as described in Items I, II, and III, below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons. I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change The Exchange proposes to amend the Opening Process for foreign currency options and also amend a reference to All-or-None Orders. The text of the proposed rule change is available on the Exchange’s Web site at www.ise.com, at the principal office of the Exchange, and at the Commission’s Public Reference Room. sradovich on DSK3GMQ082PROD with NOTICES II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The 1 15 2 17 U.S.C. 78s(b)(1). CFR 240.19b–4. VerDate Sep<11>2014 19:59 May 26, 2017 Jkt 241001 Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements. A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change 1. Purpose The purpose of this rule change is to amend GEMX Rule 701, entitled ‘‘Opening,’’ to: (i) Conform certain rule text to that of Nasdaq ISE, LLC; (ii) amend the Opening Process for foreign currency options; and (iii) remove a specific rule text reference in Rule 701 related to All-or-None Orders. Conform Rule Text ISE recently filed to adopt a new Opening Process.3 In adopting this rule, certain non-substantive modifications were made to the rule text to further clarify the manner in which the Opening Process occurs. At this time, the Exchange proposes to amend GEMX Rule 701 to conform the text of the rule to ISE Rule 701. Specifically, the Exchange proposes to amend Rule 701(j)(5) to amend the last sentence to make clear that any unexecuted contracts from the imbalance process which are not traded or routed will be cancelled back to the entering participant if they remain unexecuted and priced through the Opening Price, otherwise orders will remain in the Order Book. The additional language adds more detail about the interaction with the Order Book to the rule. Foreign Currency Options GEMX Rule 701 provides that Market Maker Valid Width Quotes and Opening Sweeps received starting at 9:25 a.m. Eastern Time, or 7:25 a.m. Eastern Time for U.S. dollar-settled foreign currency options, will be included in the Opening Process. Orders entered at any time before an option series opens are included in the Opening Process. The current Opening Process rule states that the submission of Valid Width Quotes and Opening Sweeps for U.S. dollarsettled foreign currency options may begin at 7:25 a.m. Eastern Time to tie the option Opening Process to quoting in the underlying security 4; it presumes that option quotes submitted before any indicative quotes have been disseminated for the underlying security may not be reliable or intentional. The Exchange proposes to amend GEMX 3 See Securities Exchange Act Release No. 80225 (March 13, 2017), 82 FR 14243 (March 17, 2017) (SR–ISE–2017–02). 4 The underlying security can also be an index. PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 24751 Rule 701 so that the Opening Process for foreign currency options would initiate on or after 9:30 a.m. Eastern Time and the Market Maker Valid Width Quotes and Opening Sweeps would be considered for the Opening Process starting at 9:25 a.m. Eastern Time for foreign currency options. All-or-None Orders The Exchange also proposes to amend Rule 701 to remove a specific reference to the manner in which All-or-None Orders are treated in the Opening Process. The Exchange filed a proposed rule change to amend All-or-None Orders.5 The Exchange amended Rule 715(c) to provide that an All-or-None Order may only be entered into the System with a time-in-force designation of Immediate-or-Cancel 6 Order in connection with the Exchange’s technology migration to INET. Previously, All-or-None Orders could trade as a limit or market order to be executed in its entirety or not at all. With the amendment, an All-or-None Order does not persist in the Order Book. The carve out specified in Rule 701(j)(6)(i) is unnecessary since an Allor-None Order will execute immediately or cancel. The Exchange believes removing this reference will eliminate confusion. 2. Statutory Basis The Exchange believes that its proposal is consistent with Section 6(b) of the Act,7 in general, and furthers the objectives of Section 6(b)(5) of the Act,8 in particular, in that it is designed to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general to protect investors and the public interest for the reasons stated below. Conform Rule Text The Exchange believes that conforming the GEMX rule to the ISE rule will avoid confusion for market participants. The Opening Process is the same on these two markets. By conforming the rule text of these two rules will make clear that there is no difference in the operation of these two Opening Processes. 5 See Securities Exchange Act Release No. 80102 (February 24, 2017, 82 FR 12381 (March 2, 2017) (SR–ISEGemini–2017–08) (Notice of Filing and Immediate Effectiveness of Proposed Rule Change Related to All-or-None Orders). 6 An Immediate-or-Cancel Order is a limit order that is to be executed in whole or in part upon receipt. Any portion not so executed is to be treated as cancelled. 7 15 U.S.C. 78f(b). 8 15 U.S.C. 78f(b)(5). E:\FR\FM\30MYN1.SGM 30MYN1

Agencies

[Federal Register Volume 82, Number 102 (Tuesday, May 30, 2017)]
[Notices]
[Pages 24750-24751]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10967]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[NRC-2017-0013]


Information Collection: ``10 CFR Part 35, Medical Use of 
Byproduct Material''

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of submission to the Office of Management and Budget; 
request for comment.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has recently 
submitted a request for renewal of an existing collection of 
information to the Office of Management and Budget (OMB) for review. 
The information collection is entitled, ``10 CFR part 35, Medical Use 
of Byproduct Material.''

DATES: Submit comments by June 29, 2017.

ADDRESSES: Submit comments directly to the OMB reviewer at: Aaron 
Szabo, Desk Officer, Office of Information and Regulatory Affairs, OMB 
clearance number 3150-0010, NEOB-10202, Office of Management and 
Budget, Washington, DC 20503; telephone: 202-395-3621, email: 
oira_submission@omb.eop.gov.

FOR FURTHER INFORMATION CONTACT: David Cullison, NRC Clearance Officer, 
U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; 
telephone: 301-415-2084; email: INFOCOLLECTS.Resource@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Obtaining Information and Submitting Comments

A. Obtaining Information

    Please refer to Docket ID NRC-2017-0013 when contacting the NRC 
about the availability of information for this action. You may obtain 
publicly-available information related to this action by any of the 
following methods:
     Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC-2017-0013. A copy of 
the collection of information and related instructions may be obtained 
without charge by accessing Docket ID NRC-2017-0013 on this Web site.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``ADAMS Public Documents'' and 
then select ``Begin Web-based ADAMS Search.'' For problems with ADAMS, 
please contact the NRC's Public Document Room (PDR) reference staff at 
1-800-397-4209, 301-415-4737, or by email to pdr.resource@nrc.gov. The 
supporting statement is available in ADAMS under Accession No. 
ML16333A028.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.
     NRC's Clearance Officer: A copy of the collection of 
information and related instructions may be obtained without charge by 
contacting the NRC's Clearance Officer, David Cullison, Office of the 
Chief Information Officer, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555-0001; telephone: 301-415-2084; email: 
INFOCOLLECTS.Resource@NRC.GOV.

B. Submitting Comments

    The NRC cautions you not to include identifying or contact 
information that you do not want to be publicly disclosed in your 
comment submission. The NRC posts all comment submissions at https://www.regulations.gov as well as entering the comment submissions into 
ADAMS. The NRC does not routinely edit comment submissions to remove 
identifying or contact information.
    If you are requesting or aggregating comments from other persons 
for submission to the OMB, then you should inform those persons not to 
include identifying or contact information that they do not want to be 
publicly disclosed in their comment submission. Your request should 
state that the NRC does not routinely edit comment submissions to 
remove such information before making the comment submissions available 
to the public or entering the comment submissions into ADAMS.

Background

    Under the provisions of the Paperwork Reduction Act of 1995 (44 
U.S.C. Chapter 35), the NRC recently submitted a request for renewal of 
an existing collection of information to OMB for review entitled, ``10 
CFR part 35, Medical Use of Byproduct Material.'' The NRC hereby 
informs potential respondents that an agency may not conduct or 
sponsor, and that a person is not required to respond to, a collection 
of information unless it displays a currently valid OMB control number.
    The NRC published a Federal Register notice with a 60-day comment 
period on this information collection on February 1, 2017 (82 FR 8959).
    1. The title of the information collection: ``10 CFR part 35, 
Medical Use of Byproduct Material.''
    2. OMB approval number: 3150-0010.
    3. Type of submission: Extension.
    4. The form number if applicable: N/A.
    5. How often the collection is required or requested: Reports of 
medical events, doses to an embryo/fetus or nursing child, or leaking 
source are reportable on occurrence. A specialty board certifying 
entity desiring to be recognized by the NRC must submit a one-time 
request for recognition and infrequently revise the information.
    6. Who will be required or asked to respond: Physicians and medical 
institutions holding an NRC license authorizing the administration of 
byproduct material or radiation from this material to humans for 
medical use. A specialty board certification entity desiring to have 
its certifying process and board certificate recognized by the NRC.
    7. The estimated number of annual responses: 276,359 ((NRC: 36,313 
+ 962 recordkeepers = 37,275) + (Agreement States: 232,925 + 6,157 
recordkeepers + 2 specialty certification entity = 239,084)).
    8. The estimated number of annual respondents: 7,121(NRC: 962 + 
Agreement states 6,157 + 2 specialty certification entities).
    9. An estimate of the total number of hours needed annually to 
comply with the information collection requirement or request: 
1,073,224 hours (NRC Licensees 145,195 hrs. + Agreement States 928,027 
hrs. + specialty certifying entities 2 hrs.).
    10. Abstract: ``10 CFR part 35, Medical Use of Byproduct 
Material,'' contains NRC's requirements and provisions for the medical 
use of byproduct material and for issuance of specific licenses 
authorizing the medical use of this material. These requirements and 
provisions provide for the radiation safety of workers, the general 
public, patients, and human research subjects. Part 35 contains 
mandatory requirements that apply to NRC licensees authorized to 
administer byproduct material or radiation therefrom to humans for 
medical use. These requirements also provide voluntary provisions for 
specialty boards to apply to have their certification processes 
recognized by the

[[Page 24751]]

NRC so that their board certified individuals can use the 
certifications as proof of training and experience.

    Dated at Rockville, Maryland, this 23rd day of May 2017.

    For the Nuclear Regulatory Commission.
David Cullison,
NRC Clearance Officer, Office of the Chief Information Officer.
[FR Doc. 2017-10967 Filed 5-26-17; 8:45 am]
 BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.